header-17
Translational Research

Presentations 2017

In 2017, APCRC-Q research fellows and students have given the following at national and international conferences:

Australasian Genomic Technologies Association Annual Conference, Hobart, 29 October – 1 November 2017.

Poster: Matin F, Jeet V, Moya L, Clements J, Batra J, The Theranostic Potential of MicroRNAs in Aggressive Prostate Cancer.

28th Annual Conference of the European Society for Biomaterials (ESB), Greece, Athens, 4-8 September 2017.

Oral: Bock N, Shokoohmand A, Kryza T, Rohl J, Hutmacher DW, Clements J, Quantification of Metastatic Prostate Cancer - Exploiting an In Vitro Engineered Human Bone Microenvironment.

Falling Walls Lab, Canberra, 12 September 2017.

Oral: Srinivasan S, Kryza T, Bock N, Stephens C, The PRACTICAL Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Breaking the Wall of Prostate Cancer Diagnosis.

The 7th Biannual International Symposium on Kallikreins and Kallikrein-related Peptidases, Tours, France, 26-29 September 2017:

Invited plenary speaker: Clements J, Dysregulation of the proteolytic network in prostate cancer cells after androgen targeting therapies: Focus on KLK14.

Invited speaker: Jyotsna Batra: Kallikreins in post-GWAS era.

Oral: Kryza T, The kallikrein-related peptidases are actively involved in the remodelling of the tumour microenvironment.

Poster: Srinivasan S, Kryza T, Bock N, Stephens C, Rohl J, Dong Y, Panchadsaram J, Lilja H, Spurdle A, Koistinen H, The PRACTICAL Consortium, Australian Prostate Cancer.

BioResource, Judith Clements J, Batra J. Prostate cancer-risk associated germline variants in the PSA/KLK3 gene have a clinical impact.

The 18th Asia-Pacific Prostate Cancer Conference, Melbourne, 30 August - 2 September 2017:

Invited speaker: Nelson C, Endocrine reprograming triggered by treatment with androgen targeted therapies.

Invited speaker: Clements J, Clinical and functional impact of prostate cancer risk associated germline variants in the PSA/KLK3 gene.

Invited speaker: Hollier B, Targeting the adaptive plasticity response to androgen targeted therapies.

Invited speaker: Chopin L, The prostate cancer associated long non coding RNA, GHSROS, promotes tumourigenesis and is a potential therapeutic target for advanced prostate cancer.

Poster: Subramaniam S, PDK1 dependent aerobic glycolysis and tumorigenesis in prostate cancer is regulated by miRNAs in an allele dependent manner.

Poster: Rhee H, Nicholson C, Gunter J, Nelson C, Molecular mechanisms of metformin in prostate cancer – Mitochondrial toxicity and apoptosis.

Poster: Rhee H, Nicholson C, Jovanovic L, Williams E, Corcoran N, Gunter J, Vela I, Nelson CC, Androgen Deprivation Therapy induced rise in leptin level can be reduced with Metformin: Results from ADMET trial.

The Joint Annual Scientific Meetings of the Endocrine Society of Australia and the Society for Reproductive Biology 2017, Perth, 27 – 30 August 2017:

Maugham M, Thomas P, Crisp G, Philp L, Shah E, Herington A, Chen C, Gregory L, Nelson C, Seim I, Jeffery P, Chopin L, Insights from engraftable immunodeficient mouse models of hyperinsulinaemia

Shah E, Thomas PB, Jeffery PL, Nelson CC, Gahete MD, Luque RM, Seim I, Chopin LK, A role for the long non-coding RNA GHRLOS in cancer

The IHBI Inspires Conference, Brisbane, 23 – 24 August 2017:

Oral: Hollier B, Targeting the adaptive plasticity response to androgen-targeted therapies in advanced prostate cancer.

Oral: Maugham M, Insights from engraftable immunodeficient mouse models of hyperinsulinaemia.

Poster: Srinivasan S, Kryza T, Bock N, Stephens C, The PRACTICAL Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Personalizing the ‘PSA test’ for prostate cancer diagnosis.

Poster: Panchadsaram J, Tevz G, Rockstroh A, Taherian Fard A, Lehman M, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. Iroquois-Homeobox 4: A novel co-regulator of androgen receptor transcriptome in prostate cancer.

Poster: Matin F, Jeet V, Moya L, Clements J, Batra J. Towards Novel miRNA Based Theranostic Approaches in Aggressive Prostate Cancer.

Poster: Subramaniam S, Jeet J, Walpole C, Nelson C, Gunter JH, Clements J, Batra J.   PDK1 dependent aerobic glycolysis and tumorigenesis in prostate cancer is regulated by miRNAs in an allele dependent manner.

The Princess Alexandra Hospital Health Symposium Research Excellence Awards, 2-4 August 2017:

Oral: Subramaniam S, Jeet V, Walpole C, Nelson C, Gunter JH, Clement J, Batra J. PDK1 dependent aerobic glycolysis and tumorigenesis in prostate cancer is regulated by miRNAs in an allele dependent manner.

Poster: Matin F, Jeet V, Moya L, Clements J, Batra J. The Theranostic Potential of MicroRNAs in Aggressive Prostate Cancer.

Poster: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Srinivasan S, Kryza T, Bock N, Stephens C, The PRACTICAL Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Prostate cancer-risk associated germline variants in the PSA/KLK3 gene have a clinical impact.

The Proteases and the Tumori Microenvironment Symposium, Prato, Italy, 24-26 July 2017:

Invited speaker: Clements J, Proteases are critical players in the TME.
Invited speaker: Kryza T, Modulation of protease expression in prostate cancer cells after androgen targeted therapy: A focus on KLK14.

Poster:  Kryza T, Fuhrman-Luck R, Stephens C, Lawrence M, Risbridger G, Clements J.  Involvement of the kallikrein-related peptidase 4 in the interactions cancer cells and stromal cells.

The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Melbourne, 16-18 July 2017:  

Invited speaker: Williams ED, Targeting the microenvironment in osteoblastic prostate cancer bone metastases.

Invited speaker: Gunter J, Targeting metabolic dysfunction induced by ADT in advanced prostate cancer. 

Poster: Srinivasan S, Kryza T, Bock N, Stephens C, The PRACTICAL Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Prostate cancer-risk associated germline variants in the PSA/KLK3 gene have a clinical impact.  

Poster: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Matin F, Jeet V, Moya L, Clements J, Batra J. The Theranostic Potential of MicroRNAs in Aggressive Prostate Cancer.  

Poster: Subramaniam S, Jeet V, Walpole C, Nelson C, Gunter JH, Clements J, Batra J. Determining the functional roles of PDK1 and MCAT genes in prostate cancer.

The 2017 Australian Society for Medical Research (ASMR) Queensland Health & Medical Research Awards Seminar, Brisbane, 31 May 2017:

Oral: Vela I, Development of a precision medicing program in prostate cancer (Clinical Researcher award)

Oral: Bock N, Kryza T, Rohl J, Shokoohmand A, Nelson C, Hutmacher DW, Clements J, Quantification of metastatic prostate cancer and anti-androgens therapies – Exploiting an in vitro engineered human bone-like microenvironment. (Postdoctoral Researcher award)

Oral: Batra J, A large scale association analysis of miRSNPs with prostate cancer

Oral: Subramaniam S, Jeet V, Walpole C, Nelson C, Gunter JH, Clements J, Batra J, PDK1 dependent aerobic glycolysis and tumorigenesis in prostate cancer is regulated by miRNAs in an allele dependent manner.

Poster: Ratther E, Sweeney K, Hu Q, Stylianou N, Tevz G, Nelson C, Williams ED, Hollier BG, Unravelling the role of androgen targeted therapies in epithelial plasticity during prostate cancer progression

Poster: Srinivasan S, Stephens C Clements J, Batra J. Prostate cancer-risk associated germline variants in the PSA/KLK3 gene have a clinical impact.

Poster: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated multiple-nucleotide length polymorphism regulates androgen-mediated expression of IRX4.
Poster: Matin F, Jeet V, Moya L, Clements J, Batra J. The Theranostic Potential of MicroRNAs in Aggressive Prostate Cancer.

Cure Cancer Australia Research Symposium, Sydney, 16-17 May 2017:

Oral presentation: Batra J, The long and short of a GWAS identified long noncoding RNA.

The 2nd Australian Cancer and Metabolism Meeting, Melbourne, 15-17 May 2017:

Invited speaker: Nelson C, Role of androgens and androgen targeted therapies in prostate tumour cell metabolism.

Oral: Tousignant K, Gunter JH, Philp L, Nelson CC, Sadowski MC, Enhanced lipid uptake: A novel metabolic target to fight the adaptive response to androgen-targeted therapies in prostate cancer

Poster: Philp LK, Ratther E, Gunter JH , Tevz G, Liberio MS, Lehman M, Otvos L, Sadowski MC, Nelson CC. Leptin Receptor Antagonist, Allo-Aca, Inhibits Androgen-Deprived Prostate Cancer Cell Invasiveness In Vitro & Hinders Prostate Cancer Xenograft Progression In Vivo

Poster: Gunter J, Rhee H, Philp L, Levrier C, Lehman M, Vela I, Sadowski M, Nelson CC, Combined androgen deprivation and biguanide treatment modulates autophagy and apoptosis in prostate cancer cells

Poster: Liberio MS, Sadowski MC, Wang Q, Gunter JH, Rockstroh A, Hardie R-A, Pang A, Holst J, Davis RA, Nelson CC, Targeting of serine biosynthesis and one-carbon metabolism in prostate cancer.

Poster: Levrier C, Gunter JH, Liberio MS, Davis RA, Nelson CC, Sadowski MC, High-content screening of small molecules from nature that target prostate cancer metabolism.

The American Urological Association Conference, Boston, 12–16 May 2017:

Podium: Joshi A, Nicholson C, Hutchinson A, McPherson S, Rhee H, Gunter J, Williams E, Nelson C, Vela I, Novel in vitro organoid technology to facilitate a precision medicine approach in the management of men with biochemical recurrence of prostate cancer.

Poster: Joshi A, Nicholson C, Rhee H, McKenzie I, Munns J, Malone G, Chung E, Heathcote P, Preston  J, Lawson M, Wood S, Gustafson S, Miles K, Vela I, Exploring the clinical uptake  and use of PSMA PET MRI hybrid imaging in prostate cancer patients at an academic center in Australia.

Australasian Society of Biomaterials and Tissue Engineering (ASBTE) Annual Conference, Canberra, 18-20 April 2017:

Oral: Bock N, Shokoohmand A, Kryza T, Rohl J, Clements J, Hutmacher DW, Engineering In Vitro 3D Tumour Microenvironments for the Study of Prostate Cancer Metastasis in Bone. 

Eight posters at the American Association of Cancer Research Annual Meeting, Washington, 1-5 April 2017:

Poster: Ratther E, Sweeney K, Hu Q, Stylianou N, Tevz G, Nelson C, Williams ED, Hollier BG, Unravelling the role of androgen targeted therapies in epithelial plasticity during prostate cancer progression

Poster: Shah E, Thomas PB, Jeffery PL, Nelson CC, Gahete M, Luque R, Seim I, Chopin LK, A Role for the Novel Long Non-Coding RNA GHRLOS in Cancer.

Poster: Sweeney K, Stylianou N, Tevz G, Rockstroh A, Taherian-Fard A, Fazli L, McPherson S, Prilo K, Upadhyaya A, Williams ED, Gunter J, Lehman M, Gleave M, Nelson CC, Hollier BG. Androgen-targeted therapy induces ZEB1 expression in prostate cancer and ZEB1 is associated with suppression of androgen signalling and therapy resistance.

Poster: Upadhyaya A, Stylianou N, Hollier B, Williams ED, Reversion of Epithelial to Mesenchymal Transition under Androgen Deprived Conditions Promotes Chemoresistance in Prostate Cancer.

Poster: Volpert M, Tse BWC, Ratther E, Stylianou N, Nouri M, Lehman ML, McPherson SJ, Roshan-Moniri M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gleave ME, Williams ED, Rennie PS, Buttyan R, Russell PJ, Nelson CC, Hollier BG. Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastatic progression and patient mortality.

Poster: Maugham M, Thomas PB, Crisp GJ, Philp LK, Shah ET, Herington AC, Chen C, Gregory LS, Nelson CC, Seim I, Jeffery PL, Chopin LK, Insights from engraftable immunodeficient mouse models of hyperinsulinaemia.

Poster: Hu Q, Ratther E, Sweeney K, Tse B, Nelson CC, Russell PJ, Williams ED, Hollier BG, Monitoring tumor grown and oxygen distribution of prostate cancer xenografts in vivo using ultrasound and photoacoustic imaging.

Poster: Thomas PB, Jeffery PL, Whiteside E, Walpole C, Maugham M, Jovanovic L, Gunter JH, Nelson CC, Herington AC, Veedu R, Chopin LK, Seim I. The long non-coding RNA GHSROS mediates expression of genes associated with tumor growth metastasis and adverse disease outcome.

 The Endocrine Society Annual Meeting, Orlando, USA, 1-4 April 2017:

    Poster: Philp L, Nelson C. Leptin receptor antagonist, allo-aca, inhibits androgen-deprived prostate cancer cell invasiveness in vitro and hinders prostate cancer xenograft progression in vivo.

    Poster: Philp L, Tevz G, Sadowski MC, Lehman M, Gunter JH, Nelson CC. Implicating the Glucagon-like peptides in the metabolic reprogramming observed in response to Androgen Deprivation Therapy in advanced prostate cancer.

    Tumor Metabolism: Mechanisms and Targets and Adaptations to Hypoxia in Physiology and Disease, 4-10 March 2017:

    Subramaniam S, Jeet V, Walpole C, Nelson C, Gunter JH, Clements J, Batra J. PDK1 dependent aerobic glycolysis and tumorigenesis in prostate cancer is regulated by miRNAs in an allele dependent manner.

    9th HOPE meeting with Nobel Laureates, Tokyo, Japan, 27 February – 2 March 2017:

    Poster: Bock N, Shokoohmand A, Kryza T, Rohl J, Clements J, Hutmacher DW, A 3D Bioengineered In Vitro Model for Prostate Cancer Bone Metastasis.

    Oral: Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Vela I, Nelson C. Metformin can reduce cardiovascular risk factors in men treated with androgen deprivation therapy, USANZ 2017 Annual Scientific Meeting, Canberra, 24-27 February 2017